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Abstract
Background: Carcinoid heart disease, a known complication of neuroendocrine tumors, is characterized by right heart 
fibrotic lesions. Carcinoid heart disease has traditionally been defined by the degree of valvular involvement. Right 
ventricular (RV) dysfunction due to mural involvement may also be a manifestation. Connective tissue growth factor 
(CCN2) is elevated in many fibrotic disorders. Its role in carcinoid heart disease is unknown. We sought to investigate 
the relationship between plasma CCN2 and valvular and mural involvement in carcinoid heart disease.
Methods: Echocardiography was performed in 69 patients with neuroendocrine tumors. RV function was assessed 
using tissue Doppler analysis of myocardial systolic strain. Plasma CCN2 was analyzed using an enzyme-linked 
immunosorbent assay. Mann-Whitney U, Kruskal-Wallis, Chi-squared and Fisher's exact tests were used to compare 
groups where appropriate. Linear regression was used to evaluate correlation.
Results: Mean strain was -21% ± 5. Thirty-three patients had reduced RV function (strain > -20%, mean -16% ± 3). Of 
these, 8 had no or minimal tricuspid and/or pulmonary regurgitation (TR/PR). Thirty-six patients had normal or mildly 
reduced RV function (strain ≤ -20%, mean -25% ± 3). There was a significant inverse correlation between RV function 
and plasma CCN2 levels (r = 0.47, p < 0.001). Patients with reduced RV function had higher plasma CCN2 levels than 
those with normal or mildly reduced RV function (p < 0.001). Plasma CCN2 ≥ 77 μg/L was an independent predictor of 
reduced RV function (odds ratio 15.36 [95% CI 4.15;56.86]) and had 88% sensitivity and 69% specificity for its detection 
(p < 0.001). Plasma CCN2 was elevated in patients with mild or greater TR/PR compared to those with no or minimal 
TR/PR (p = 0.008), with the highest levels seen in moderate to severe TR/PR (p = 0.03).
Conclusions: Elevated plasma CCN2 levels are associated with RV dysfunction and valvular regurgitation in NET 
patients. CCN2 may play a role in neuroendocrine tumor-related cardiac fibrosis and may serve as a marker of its earliest 
stages.
Background
Neuroendocrine tumors (NETs) are derived from the diffuse neuroendocrine cell system which is made up of cells that
release hormones in response to signals from the nervous system. NETs most commonly arise from the gastrointestinal
tract and the bronchopulmonary system. Carcinoid heart disease (CHD) is a known complication of these tumors, par-
ticularly of those arising from the small intestine, appendix and proximal colon (previously known as mid-gut carcino-
ids). CHD is characterized by plaque-like subendothelial lesions which are caused by proliferation of myofibroblasts
and increased deposition of extracellular matrix [1,2]. These lesions result in retraction and fixation of the heart valves
which in some cases may necessitate surgery.
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Although CHD affects both mural and valvular endo-
cardium, the condition has traditionally been defined by
the degree of valvular involvement present most com-
monly in the form of tricuspid regurgitation. The criteria
for CHD varies between studies with some including
patients with at least mild or greater valvular involvement
[2,3], while others limit the criteria to moderate or severe
valvular pathology [4]. However, impaired right ventricu-
lar (RV) function due to fibrosis of the mural wall could
potentially be an earlier manifestation of CHD.
Connective tissue growth factor (CCN2) is a 38 kDa
cystein-rich secreted immediate early gene product and
is a member of the CCN (Cyr61/CEF-10, CTGF/Fisp-12
and Nov) family of matricellular proteins. These proteins
function as adaptor molecules linking the cell surface
with extracellular matrix and act via integrins and proteo-
glycans [5,6]. CCN2 is upregulated in many fibrotic dis-
ease processes including hepatic and renal fibrosis,
radiation enteritis and systemic sclerosis [7-11]. In addi-
tion, animal studies have shown increased expression of
CCN2 in various forms of myocardial fibrosis including
diabetic cardiomyopathy, pressure-overload cardiac
hypertrophy and in ischemic heart failure [12-14]. More-
over, expression of CCN2 mRNA is significantly elevated
in human heart tissue from patients with cardiac isch-
emia compared to normal controls [15]. It has been
shown that plasma CCN2 is elevated in patients with
small intestinal NETs compared to healthy controls, and
that patients with small intestinal NETs associated with
peritoneal fibrosis have increased tumor expression of
CCN2 compared to patients without evidence of intraab-
dominal fibrosis [16]. However, at present, it is not
known what role CCN2 may play in the development of
CHD.
A s s e s s m e n t  o f  m y o c a r d i a l  s t r a i n  i s  a n  e m e r g i n g
echocardiographic tool for evaluating RV function and
has been validated in clinical studies [17-19]. It is not
known whether there exists a relationship between CCN2
and RV function. Furthermore, to our knowledge, no
published studies using assessment of strain to evaluate
RV function in NET patients exist in the current litera-
ture.
We hypothesized that CCN2 could be involved in the
pathogenesis of CHD, and in the current study, this
hypothesis was examined by different experimental
approaches. First, we measured plasma levels of CCN2 in
a well-characterized population of patients with NETs
and in sex- and age-matched healthy controls. Second, we
examined the relationship between plasma levels of
CCN2 and the degree of tricuspid or pulmonary valve
involvement in the patient group. Finally, we assessed the
r e l a t i o n s h i p  b e t w e e n  p l a s m a  l e v e l s  o f  C C N 2  a n d  R V
function by means of RV lateral strain measurements in




Eighty-seven consecutive patients with histologically ver-
ified small intestinal (n = 84), appendiceal (n = 2) or prox-
imal colonic (n = 1) NETs admitted to the
gastroenterology ward between September 1, 2006 and
September 1, 2007, for either first-time evaluation of a
newly diagnosed NET or for follow-up, were screened for
inclusion in this prospective study. Exclusion criteria
included the presence of another fibrotic disease such as
systemic sclerosis, age < 18 or the inability to give
informed consent. W e wanted to focus on the possible
influence of active NETs, and accordingly, patients who
had undergone radical surgery were not included in the
study. Thus, only patients with residual tumor were
included, resulting in a total number of 69 out of 87
screened patients. A 24-hour urine collection for 5-
hydroxyindoleacetic acid (U-5HIAA) (normal range 0.8-
3.8 μmol/mmol creatinine) was obtained. All of the
patients routinely underwent CT examination of the
abdomen as part of their admission (separate from the
study). In order to assess tumor burden, reanalysis of the
abdominal CT scans was performed to determine the
number and size of liver metastases for each patient. The
maximal diameter of each liver metastasis was deter-
mined and then the average maximal diameter of the
total number of liver metastases for each patient was cal-
culated. For comparison of plasma levels of CCN2, 18
age-and sex-matched healthy controls were also included.
Demographic, clinical and tumor characteristics are
given in  1.
Blood sampling protocol
Peripheral venous blood was drawn from all patients and
c o n t r o l s  i n t o  p y r o g e n - f r e e  b l o o d  c o l l e c t i o n  v i a l s  w i t h
EDTA as the anticoagulant, immediately immersed in ice
and centrifuged within 1 hour at 2500 g for 20 minutes to
obtain platelet-poor plasma. All samples were stored at -
80°C and thawed only once.
Biochemical measurements
Plasma levels of CCN2 were measured using a sandwich
enzyme-linked immunosorbent assay (ELISA). Briefly,
assay plates were coated with monoclonal anti-human
CCN2 IgG1 raised against a peptide from the carboxyl-
t e r m i n a l  d o m a i n  o f  C C N 2  ( M A B 6 6 0 ,  R & D  S y s t e m s ,
Abingdon, UK) and incubated at 4°C overnight (20 μg/ml
in phosphate buffered saline [PBS]). After blocking non-
specific binding sites for 2 hours with blocking buffer
containing 1% bovine serum albumin (BSA), 100 μL of
plasma samples diluted in 100 μL assay buffer (containing
50 mM Tris pH 7.8, 0.1% BSA, Triton X-100 and heparin)
were added in duplicates to the microwells. StandardBergestuen et al, BMC Cancer 2010, 10:6
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curve was obtained from dilutions of recombinant
human CCN2 in 50% calf serum, contract-purified by
EMP Genetech (Ingolstadt, Germany). The plates were
then incubated overnight at 4°C with gentle shaking,
washed with PBS including 0.5 ml/L Tween 20, before
biotinylated goat anti-human CCN2 IgG (BAF660, R&D
Systems) (2 μg/ml) was added and incubated for 2 hours
with shaking. Plates were washed, followed by incubation
with streptavidin-HRP (DakoCytomation, Glostrup, Den-
mark) and finally, substrate reagent TMB (R&D Systems)
was added. Color development was stopped after 20 min-
utes at 37°C with H2SO4. Absorbance was measured at
450 nm. The calibration curve was fitted through use of a
5-parameter logistic function (r2 = 0.999). The intra-assay
variation (CV) was 8.7% (125 μg/L). The lower limit of
detection was 7.8 μg/L. After dilution, 5 of the samples
still had CCN2 levels above the upper limit of detection
(4000 μg/L) and accordingly, were assigned this value. All
samples were analyzed simultaneously. Patient blood
samples were additionally analyzed for chromogranin A
(CgA), a known tumor marker for neuroendocrine
Patient subgroups Figure 1 Patient subgroups. Flow chart showing patient subgroups based on either right ventricular (RV) function or the absence or presence of 
right-sided valvular regurgitation (TR/PR = tricuspid and/or pulmonary regurgitation).
Table 1: Clinical and Tumor Characteristics
Characteristic* Normal/mildly













Men 13 (36%) 20 (61%) 11 (38%) 22 (55%)
Women 23 (64%) 13 (39%) 18 (62%) 18 (45%)
Age§ 63 (36-81) 65 (33-83) 0.87 60 (36-75) 68 (33-83) <0.001
Smoking 5 (15%) 9 (28%) 0.23 5 (17%) 9 (24%) 0.56
Illness duration (yrs) 3.4 (0.8-7.5) 5.1 (2.3-6.8) 0.33 2.3 (0.7-5.2) 5.3 (2.6-7.8) 0.01
1° tumor size (mm) ? 20 (15-27) 20 (15-30) 0.44 20 (16-30) 19 (15-29) 0.53
Carcinoid syndrome¶ 30 (83%) 29 (88%) 0.74 21 (72%) 38 (95%) 0.01
Ki 67# 2% (0-10) 2.5% (1-25) 0.16 2% (1-10) 2% (0-25) 0.20
U-5HIAA** 6 (2-19) 19 (4-29) 0.08 7 (2-19) 10 (3-30) 0.21
CgA†† 14 (6-24) 26 (12-82) 0.02 16 (6-37) 19 (9-79) 0.31
Liver metastases 30 (83%) 30 (91%) 0.48 27 (93%) 33 (83%) 0.29
Size (mm)‡‡ 15 (7-19) 15 (13-25) 0.18 14 (9-19) 17 (11-24) 0.22
Number 6 (1-12) 11 (6-20) 0.01 6 (1-10) 11 (5-20) 0.03
*Results given as median (interquartile range) or n (%) unless otherwise specified. †Right ventricular function. ‡Tricuspid and/or pulmonary regurgitation.
§Median (range). ? Maximal diameter of the primary tumor. ¶Defined as flushing and/or diarrhea. #Proliferation index given as median (range). **Urinary 5-
hydroxyindoleacetic acid (normal 0.9-3.8 μmol/mmol creatinine). ††Chromogranin A (normal < 4 nmol/L). ‡‡Median maximal diameter.Bergestuen et al, BMC Cancer 2010, 10:6
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tumors [20], using a radioimmunoassay provided by
EuroDiagnostica (Malmö, Sweden) (normal <4 nmol/L).
Echocardiographic Examination
Patients were evaluated with transthoracic 2-dimen-
sional, M-mode and Doppler echocardiography using
Vivid 7 (GE Healthcare, Horten, Norway) and analyzed
with commercially available software (EchoPAC®, GE).
Two cardiologists well experienced in echocardiography
reviewed the echocardiographic registrations off-line on
a dedicated work station (EchoPacPC, GE Vingmed).
They were blinded to patients' symptoms, clinical status
and biochemical data. The severity of valvular regurgita-
tion was determined according to standard guidelines
[21,22]. Valvular regurgitation was graded as mild, mild-
to-moderate, moderate or severe [22]. CHD was defined
as the presence of right-sided valvular regurgitation or
stenosis (excluding both trivial or mild findings [23]) plus
morphologic changes including thickening, shortening,
retraction, hypomobility or incomplete coaptation of the
affected valves [2,4]. In order to assess the relationship
between CCN2 and impaired RV strain as a possible early
manifestation of CHD, the patients were further divided
into groups with either no or minimal valvular involve-
ment or at least mild or greater valvular involvement of
the right-sided valves (Figure 1).
2D-strain echocardiography
2-D grayscale images were acquired in the standard apical
views at 67 ± 26 frames/s. Three cardiac cycles were
recorded. Myocardial deformation measurements were
performed using speckle tracking echocardiography [24-
27]. RV longitudinal systolic strain was obtained from the
apical four chamber view. Mean systolic strain from the
three lateral segments of the RV was calculated. As there
currently exists no universal criteria for defining normal
and reduced RV function using RV mean lateral strain
values, we used the median to determine our cut-off
value of -20%. However, data from a recent study lend
support to the rationality of this cut-off value. In this
study, peak systolic strain in healthy individuals was -29%
± 6, in endurance athletes (RV dilatation but normal RV
function) -27% ± 7, and in patients with impaired RV
function (global or regional hypokinesia of the RV free
wall) -17% ± 7 [28]. In another study, RV mean lateral
strain in 32 control subjects was -32% ± 12 [29]. Conse-
quently, in the present study, patients with mean lateral
strain ≤ -20% were defined as having normal or mildly
reduced RV function, while those with strain > -20% were
defined as having reduced RV function (Figure 1).
Immunohistochemistry
Biopsies of the primary tumor from five of the patients
and of a liver metastasis from two of the patients were
retrieved from pathology archives. All seven patients had
small intestinal primary tumors and widespread liver
metastases. Three of these patients had reduced RV func-
tion and five had at least mild or greater tricuspid and/or
pulmonary regurgitation (TR/PR). Four of the patients
fulfilled the criteria for CHD. Formalin-fixed sections of
gut and liver NET tissue were stained using polyclonal
rabbit anti-rat CCN2 [12] and anti-human CgA (Santa
Cruz Biotechnology, CA) IgG and anti-human smooth
muscle actin (DakoCytomation). The primary antibodies
were followed by biotinylated anti-rabbit or anti-mouse
IgG (Vector Laboratories, Burlingame, CA). The immu-
noreactivities were further amplified using avidin-biotin-
peroxidase complexes (Vectastain Elite kit, Vector Labo-
ratories). Diaminobenzidine was used as the chromogen
in a commercial metal-enhanced system (Pierce Chemi-
cal, Rockford, IL). The sections were counterstained with
hematoxylin. Omission of the primary antibody served as
negative control.
Ethics
The study complies with the Helsinki Declaration and
was approved by both the Institutional Review Board and
the Regional Ethics Committee for Research. All individ-
uals gave their written informed consent to participate in
the study.
Statistical analyses
Data for continuous variables are presented as either
median with the interquartile range or mean ± SD based
on their distribution unless otherwise specified. Mann-
Whitney U, Kruskal-Wallis, χ2 and Fisher's exact tests
were used to compare groups where appropriate. Because










21 12 3 36
Reduced RV function 82 1 43 3
Total patients 29 33 7 69
*Fisher's exact test, p = 0.02. †Tricuspid and/or pulmonary regurgitation. ‡Right ventricular function.Bergestuen et al, BMC Cancer 2010, 10:6
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of extreme outliers, logarithmic transformation of plasma
CCN2 values was performed before presentation of data
in the figures. Log10 transformation values of plasma
CCN2 were used in linear regression analysis. For all
other comparisons of plasma CCN2 levels, non-trans-
formed data were employed. Binary classifications were
derived for continuous variables using cut-off values
determined by receiver operating characteristic (ROC)
curves. Cut-off values were those values which discrimi-
nated between patients with normal or mildly reduced
RV function and those with reduced RV function, and
between patients with and without at least mild or greater
TR/PR with the greatest sensitivity and specificity [30].
These binary classifications were then used in logistic
regression. Statistical analysis was performed using SPSS 
15.0 software (SPSS Inc., Chicago, IL). P-values are two-
sided and considered significant when < 0.05.
Results
Patient characteristics
Median age of the patients was 63 years (range 33-83),
48% were men. Sixty patients (87%) had liver metastases.
Fifty-nine patients (86%) had the carcinoid syndrome
defined as the presence of flushing and/or diarrhea.
RV valvular pathology
F o r t y  p a t i e n t s  h a d  a t  l e a s t  m i l d  o r  g r e a t e r  T R / P R.  O f
these, 24 had mild, 9 had mild-to-moderate, and 7 had
moderate or severe TR/PR. Only one patient in the entire
group had pulmonary stenosis in addition to TR. None of
the patients had tricuspid stenosis. Patients with at least
mild or greater TR/PR were significantly older, had longer
duration of illness, had a higher frequency of the carci-
noid syndrome and had more numerous liver metastases
than patients with no or minimal TR/PR (Table 1). Of the
40 patients with at least mild or greater TR/PR, 15 ful-
Linear relationship between plasma connective tissue  growth factor and right ventricular strain Figure 2 Linear relationship between plasma connective tissue 
growth factor and right ventricular strain. Scatter plot showing the 
inverse relationship between plasma connective tissue growth factor 
(CCN2) levels and right ventricular strain (linear regression, r = 0.47, p < 
0.001). Due to the presence of extreme outliers, plasma CCN2 levels are 
plotted on the y-axis using a logarithmic (log10) scale.
Relationship between plasma connective tissue growth fac- tor and right ventricular function Figure 3 Relationship between plasma connective tissue growth 
factor and right ventricular function. Box plot demonstrating the re-
lationship between plasma connective tissue growth factor (CCN2) 
levels and right ventricular (RV) function. Median, interquartile ranges, 
and maximum and minimum values are shown. Due to the presence 
of extreme outliers, plasma CCN2 levels are plotted on the y-axis using 
a logarithmic (log10) scale. Plasma CCN2 levels (μg/L) are significantly 
elevated in the patients with reduced RV function (strain > -20%), 
(Mann-Whitney U test, p < 0.001).
Utility of plasma connective tissue growth factor as a predic- tor of reduced right ventricular function Figure 4 Utility of plasma connective tissue growth factor as a 
predictor of reduced right ventricular function. Receiver operating 
characteristic (ROC) curve depicting the ability of plasma connective 
tissue growth factor (CCN2) levels to predict the presence of reduced 
right ventricular (RV) function (AUC 0.82 [95% CI 0.72;0.92], p < 0.001). 
Plasma CCN2 levels ≥ 77 μg/L had 88% sensitivity and 69% specificity 
for detecting patients with reduced RV function.Bergestuen et al, BMC Cancer 2010, 10:6
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filled the criteria for CHD. Of these, 14 had TR while one
patient had only PR. One patient with moderate TR did
not have any morphologic changes of the tricuspid valve
and thus, was not included in the CHD group. Of note,
U-5HIAA (20 [6-47] vs. 6 [2-25] μmol/mmol creatinine, p
= 0.03) and CgA (26 [15-153] vs 16 [6-38] nmol/L, p =
0.02) levels were significantly elevated in the patients ful-
filling the criteria for CHD which is in agreement with
previous studies [2,4].
RV function
Data on RV lateral systolic myocardial strain were avail-
able in all 69 patients with a mean value of -21% ± 5.
Thirty-three patients had reduced RV function (strain > -
20%, mean -16% ± 3), while 36 patients had normal or
mildly reduced RV function (strain ≤ -20%, mean -25% ±
3). Of the 33 patients with reduced RV function, 8 (24%)
had no or minimal, 21 (64%) had mild or mild-to-moder-
ate, and 4 (12%) had moderate or severe TR/PR. RV strain
values were significantly lower in the group with at least
mild or greater TR/PR compared to those with no or
minimal TR/PR (-20% ± 5 vs. -22% ± 5, p = 0.03). In addi-
tion, there was a significant association between reduced
RV function and the degree of valvular regurgitation (p =
0.02) (Table 2). As shown in table 1, the patients with
reduced RV function had significantly higher CgA levels
and more numerous liver metastases and tended to have
higher U-5HIAA levels than those with normal or mildly
reduced RV function.
CCN2 in relation to RV dysfunction in NET patients
No difference in the plasma levels of CCN2 was seen
between the total patient group and sex- and age-
matched healthy controls (87 [45-171] vs. 78 μg/L [59-
347]), p = 0.59). There was also no significant difference
in plasma CCN2 levels in relation to the presence (n = 15)
or absence (n = 54) of CHD using current criteria based
on valvular pathology (116 [74-180] vs. 82 μg/L [41-169],
p = 0.20). However, several significant findings were
revealed when analyzing the relationship between CCN2
and RV dysfunction by means of RV strain examination.
First, in the patient group as a whole, there was a signifi-
cant inverse correlation between RV function and plasma
CCN2 levels (r = 0.47, p < 0.001) (Figure 2). In line with
this, plasma CCN2 levels were significantly elevated in
patients with reduced RV function compared to those
with normal or mildly reduced RV function (p < 0.001)
(Figure 3). As determined by ROC curve analysis, plasma
CCN2 levels ≥ 77 μg/L had 88% sensitivity and 69% spec-
ificity for detecting patients with reduced RV function
(AUC 0.82 [95% CI 0.72;0.92], p < 0.001) (Figure 4). Using
univariate logistic regression, plasma CCN2 levels ≥ 77
μg/L (p < 0.001), CgA levels ≥ 22 nmol/L (p = 0.007) and
number of liver metastases ≥ 8 (p = 0.01) were signifi-
cantly associated with reduced RV function. In multivari-
ate analysis, only CCN2 ≥ 77 μg/L (p < 0.001) and CgA ≥
22 nmol/L (p = 0.04) remained independent predictors of
reduced RV function (Table 3). Similar results were
Table 3: Independent Predictors of Reduced Right Ventricular Function*
Univariate Analysis† P-value Multivariate Analysis P-value
CCN2 ≥ 77 μg/L‡ 16.48 [4.66;58.28] <0.001 15.36 [4.15;56.86] <0.001
CgA ≥ 22 nmol/L§ 4.07 [1.46;11.32] 0.007 3.57 [1.03;12.29] 0.04
No. mets ≥ 8|| 3.61 [1.33;9.83] 0.01
*Logistic regression. †Results given as odds ratio (OR) with 95% confidence interval. ‡Connective tissue growth factor. §Chromogranin A (normal < 4 nmol/
L). ||Number of liver metastases.
Table 4: Plasma CCN2 and Degree of Valvular Involvement
Degree of TR/PR* # Patients Plasma CCN2*ug/L
Controls 18 78 (59-347)
None/minimal 29 60 (32-112)
Mild 24 111 (57-309)
Mild-to-moderate 9 91 (71-165)
Moderate 4 130 (40-433)
Severe 3 166 (14-4000)
*Tricuspid and/or pulmonary regurgitation. *Connective tissue growth factor. Results given as median (interquartile range).Bergestuen et al, BMC Cancer 2010, 10:6
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obtained using both forward and backward conditional
stepwise methods.
CCN2 in relation to right heart valvular involvement in NET 
patients
Plasma CCN2 levels for each of the categories of valvular
involvement are given in table 4. Patients with at least
mild or greater TR/PR had significantly higher plasma
CCN2 levels compared to patients with no or minimal
TR/PR (111 [69-279] vs 60 μg/L [32-112], p = 0.008). Fur-
thermore, when the patients were divided into three
groups according to the degree of TR/PR, there was a
gradual rise in CCN2 levels, with the highest levels seen
in those with moderate to severe TR/PR (p = 0.03) (Figure
5). Using cut-off values determined by ROC curve analy-
sis, plasma CCN2 ≥ 86 μg/L, age ≥ 67 years, presence of ≥
9 liver metastases and duration of illness ≥ 46 months
were significantly associated with at least mild or greater
TR/PR, as was presence of the carcinoid syndrome. In
multivariate analysis, only plasma CCN2 ≥ 86 μg/L (p =
0.008), age ≥ 67 years (p = 0.001) and presence of ≥ 9 liver
metastases (p = 0.04) remained independent predictors of
the presence of at least mild or greater TR/PR (Table 5).
Immunostaining of neuroendocrine tumors
Fairly strong CCN2 immunoreactivity was found in CgA
positive (tumor) tissue obtained from both the gut and
from the liver. Weaker immunostaining for CCN2 was
seen in gut smooth muscle cells (Figure 6). Positive
immunostaining was present in all seven biopsies exam-
ined, that is from both patients with and without reduced
Relationship between plasma connective tissue growth fac- tor and degree of valvular regurgitation Figure 5 Relationship between plasma connective tissue growth 
factor and degree of valvular regurgitation. Box plot displaying the 
relationship between plasma connective tissue growth factor (CCN2) 
levels and the degree of tricuspid and/or pulmonary regurgitation. Me-
dian, interquartile range, and maximum and minimum values are 
shown. Due to the presence of extreme outliers, plasma CCN2 levels 
are plotted on the y-axis using a logarithmic (log10) scale. The highest 
plasma CCN2 levels were seen in the patients with moderate to severe 
right-sided valvular regurgitation (Kruskal-Wallis test, p = 0.03).
Immunostaining of neuroendocrine tumors Figure 6 Immunostaining of neuroendocrine tumors. Representa-
tive photomicrographs demonstrating anti-connective tissue growth 
factor (CCN2) (panel A) immunostaining of gut carcinoid tumor tissue. 
CCN2 immunoreactivity was seen in cells corresponding to chromogr-
anin A-positive tumor cells and gut smooth muscle (denoted by ar-
rows in panels B and C, respectively). All sections were counterstained 
with hematoxylin. Magnification ×50.Bergestuen et al, BMC Cancer 2010, 10:6
http://www.biomedcentral.com/1471-2407/10/6
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RV function and from patients with and without at least
mild or greater TR/PR.
Discussion
In the present study, a significant inverse correlation was
found between RV function and plasma CCN2 levels.
Furthermore, patients with reduced function of the right
lateral ventricular wall had elevated plasma CCN2 levels
even in the absence of valvular regurgitation. When the
patients were grouped according to the presence or
absence of valvular regurgitation, plasma CCN2 levels
were significantly elevated in patients with at least mild
or greater TR/PR compared to those patients with no or
minimal TR/PR. Importantly, an elevated plasma CCN2
level was an independent predictor of both reduced RV
function and the presence of any right-sided valvular
regurgitation. Moreover, patients with more advanced
stages of frank CHD, that is moderate or severe valvular
involvement with associated morphologic changes, had
the highest CCN2 levels. Thus, although we found no
association between CCN2 and the presence of CHD
based on current criteria, our findings suggest that
plasma levels of CCN2 could potentially be a marker of
early cardiac fibrosis in patients with NETs reflecting
both mural and valvular pathology. As shown in figure 7,
CCN2 compares favorably to both CgA and U-5HIAA
with regard to predicting the presence of reduced RV
function.
The CCN2 protein is thought to consist of four separate
modules. Module 1 is identical to insulin-like growth fac-
tor binding protein, module 2 consists of a chordin-like
cysteine-rich domain, module 3 is composed of a throm-
bospondin type 1 domain and module 4 is designated as
the CT module or cysteine knot. Modules 1 and 2 make
up the N-terminal domain and are linked by a hinge
region to the C-terminal domain which is made up of
modules 3 and 4 [31,32]. The ELISA analysis used in our
study detects C-terminal CCN2 which translates into
detection of both C-terminal fragments and whole
CCN2. Our analysis is not able to detect N-terminal
CCN2 fragments. Other studies have evaluated the utility
of N-terminal CCN2 as a marker of intraocular fibrosis
and in scleroderma. In these studies, neither C-terminal
nor whole CCN2 were elevated in disease. As as result, it
has been postulated that during a fibrotic response, in
vivo CCN2 is cleaved resulting in N-terminal fragments
Relationship between plasma connective tissue growth factor, chromogranin A and urinary 5-hydroxyindoleacetic acid and  right ventricular function Figure 7 Relationship between plasma connective tissue growth factor, chromogranin A and urinary 5-hydroxyindoleacetic acid and right 
ventricular function. Box plots displaying the relationship between plasma connective tissue growth factor (CCN2), chromogranin A (CgA) and uri-
nary 5-hydroxyindoleacetic acid (U-5HIAA) levels and right ventricular (RV) function. Median, interquartile ranges, and maximum and minimum values 
are shown. Due to the presence of extreme outliers, values are plotted on the y-axis using a logarithmic (log e) scale. P-values are determined using 
Mann-Whitney U test.
Table 5: Independent Predictors of Mild to Severe Tricuspid or Pulmonary Regurgitation*
Univariate Analysis† P-value Multivariate Analysis P-value
CCN2 ≥ 86 μg/L‡ 5.45 [1.91;15.57] 0.002 7.76 [1.71;35.28] 0.008
Age ≥ 67 years 7.20 [2.27;22.80] 0.001 15.48 [3.00;79.89] 0.001
No. mets ≥ 9§ 3.55 [1.27;9.23] 0.02 4.56 [1.06;19.63] 0.04
Duration ≥ 46 mos|| 3.70 [1.34;10.21] 0.01
Carcinoid syndrome¶ 7.24 [1.41, 37.26] 0.02
*Logistic regression. †Results given as odds ratio (OR) with 95% confidence interval. ‡Connective tissue growth factor. §Number of liver metastases. ||Du-
ration of illness in months. ¶Defined as flushing and/or diarrhea.Bergestuen et al, BMC Cancer 2010, 10:6
http://www.biomedcentral.com/1471-2407/10/6
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which are excreted into the extracellular space. The C-
terminal fragment may remain attached to the cell mem-
brane or be internalized and degraded after exerting its
effects. These results suggest that circulating N-terminal
CCN2 may be a better marker of fibrosis [31,33]. Other
studies, however, have shown significant elevations in
whole CCN2 in patients compared to controls [34]. It is
possible that the measurement of different CCN2 frag-
ments may reveal varying strengths regarding the ability
to predict the presence of disease. Nonetheless, we have
demonstrated a significant difference in plasma CCN2
levels (C-terminal and/or whole) in patients with and
without reduced RV function and in patients with and
without any valvular regurgitation. Based on the above
studies, it is conceivable that the difference would have
been even more significant had we measured the N-ter-
minal fragment, representing a possible limitation of our
study.
It is of interest to note that in our patients, decreased
RV function was not associated with age while valvular
regurgitation was. As both decreased RV function and
valvular changes may be involved in the fibrotic process
leading to CHD, it is unclear why we found this discrep-
ancy. It is possible that valvular structures are more pre-
disposed to degenerative changes due to natural aging
than myocardial tissue. Thus, the combination of profi-
brotic conditions and increased age in patients with neu-
roendocrine tumors may make such patients especially at
risk for valvular dysfunction.
CCN2 is an immediate early gene product and some
data suggest that CCN2 expression rapidly increases in
the early stages of fibrotic processes, and then continues
to be elevated throughout the chronic phase of fibrosis
[12,13]. This may potentially explain our findings of ele-
vated CCN2 levels even in patients with decreased RV
function in the absence of right-sided valvular changes, in
other words in patients with possibly the earliest stages of
CHD. In contrast to earlier findings on serum levels of
CCN2 in NET patients [16], we did not show any differ-
ence in plasma CCN2 levels between the total patient
group and controls. However, as platelets contribute sig-
nificantly to circulating CCN2 levels through platelet
activation [34-36], it may be preferential to measure this
protein in platelet-poor plasma to avoid the influence
from platelet-mediated release of CCN2 during ex vivo
coagulation of serum. Thus, our results may not be com-
parable to studies assessing serum CCN2 levels.
As shown in figure 3, there appears to be a trend
towards lower plasma CCN2 levels in the patients with
normal/mildly reduced RV function compared to con-
trols although this difference is not significant (p = 0.054,
Kruskal-Wallis with post-hoc analysis). This suggests that
the control group has higher CCN2 values than would be
expected in a group of healthy individuals. There are sev-
eral possible reasons for this. One is that the number of
individuals in the control group is small likely making an
appropriate comparison difficult. Secondly, several of the
controls had very high levels, including one over 4000 ug/
L. In a group of only 18 controls, outliers have a greater
effect on the median and interquartile range than in a
larger group. In agreement with our findings, a recent
study evaluating the role of CCN2 as a marker of fibro-
genesis in liver disease also demonstrated extreme outli-
ers in the control group. The control group, however, was
much larger (n = 74) and they were able to show a signifi-
cant difference between controls and patients [34]. The
small size of the control group is a recognized limitation
of our study. Finally, although the control individuals
were healthy based on self-reporting, the possibility also
e x i s t s  t h a t  s o m e  o f  t h e m  m a y  h a v e  h a d  u n d i a g n o s e d
occult diseases which affect CCN2 levels. Nonetheless,
despite these limitations in the selection of the control
group, within the patient group it is clear that there is a
significant difference between plasma CCN2 levels in
patients with reduced RV function compared to those
with normal/mildly reduced RV function. Moreover, the
gradual rise along with increasing mural and valvular
pathology, clearly suggest a link between CCN2 and RV
dysfunction in NETs.
The cellular source of raised CCN2 levels in our group
of patients is currently not known. One possibility is that
the tumor cells themselves express and secrete CCN2
into the circulation which then exerts its effects upon a
d i s t a n t  o r g a n  s u c h  a s  t h e  h e a r t .  W e  s h o w e d  p o s i t i v e
immunostaining for CCN2 in tissue from both primary
small intestinal tumors and liver metastases which is in
agreement with previous findings [16], but we could not
demonstrate any gross difference in the staining of tumor
tissue in relation to strain or valvular pathology. However,
immunohistochemistry was performed in relatively few
patients, and future studies should also use more quanti-
tative methods for assessment of CCN2 in tissue samples.
Another possibility is that CCN2 expression is induced
locally in the heart by some other circulating factor, with
one likely candidate being serotonin (5-hydroxytryptam-
ine, 5-HT). NETs, especially those arising from the small
intestine, secrete vasoactive substances such as serotonin
into the circulation. It is thought that exposure of the
right heart to these vasoactive substances results in the
characteristic fibrotic lesions seen in CHD. It has been
shown that serotonin directly, via the Rho signaling path-
way [37], and indirectly, via induction of transforming
growth factor (TGF)-β [38], induces CCN2 expression in
renal mesangial cells via the Gq-coupled 5-HT2A receptor.
It is not known whether serotonin directly induces CCN2
expression in the heart. It is known, however, that sero-
tonin receptors (subtypes 5-HT1B, 1D, 2A, 2B) are normally
expressed in human heart valve interstitial cells [39,40],Bergestuen et al, BMC Cancer 2010, 10:6
http://www.biomedcentral.com/1471-2407/10/6
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and it has been shown that 5-HT2B  receptors are
expressed in human cardiac fibroblasts and cardiomyo-
cytes [41]. Moreover, in CHD lesions, 5-HT1B receptors
[42] as well as TGF-β1 and TGF-β3 are upregulated [43].
Also of interest to our study, CCN2 expression in normal
rat hearts has been shown to be mainly expressed in
endothelial cells and fibroblasts and that TGF-β induces
CCN2 mRNA expression in rat cardiac fibroblasts [12].
Although we do not have mechanistic data, it is tempting
to hypothesize that circulating serotonin may induce
CCN2 expression in cardiac fibroblasts directly as well as
via induction of TGF-β leading to increased collagen
deposition and fibrosis in both mural and valvular endo-
cardium. Whether or not elevated levels of CCN2 in neu-
roendocrine patients with decreased RV function
(possibly reflecting fibrosis in the mural endocardium)
and/or valvular involvement (fibrosis in the valvular
endocardium) is the result of circulating CCN2 acting
directly on cardiac fibroblasts or, more probably, is the
result of local increased production due to stimulation by
serotonin, remains to be seen. Nonetheless, based on the
potent fibrogenic properties of CCN2 as well as its rela-
tionship to cardiac fibrosis, we suggest that CCN2 is not
only a marker but may also be a mediator in the develop-
ment of mural and valvular pathology in patients with
NETs.
Five of the patients in our cohort had extremely ele-
vated plasma CCN2 levels (> 4000 μg/L), a finding also
documented in other studies [34]. It has been demon-
strated that polymorphisms in the CCN2 promoter exist
in normal individuals and that increased prevalence of
certain polymorphisms may be associated with fibrotic
diseases such as systemic sclerosis [44]. However, it is not
known if certain polymorphisms are associated with
higher plasma CCN2 levels. Future studies should exam-
ine whether or not any relationship between certain
CCN2 polymorphisms and the development of RV
pathology in NET patients can be demonstrated.
It is well-known that mild right-sided valvular regurgi-
tation can be a normal physiological variant in healthy
persons. Thus, we cannot say the presence of mild TR/PR
in our patients necessarily represents a pathological pro-
cess. However, we hypothesize that our patients with
mild TR/PR and elevated CCN2 levels, as well as those
patients with decreased RV function (even in the absence
of valvular changes) and elevated CCN2 levels, are in the
process of developing frank CHD, but future studies are
needed to confirm this hypothesis.
Conclusion
Elevated plasma CCN2 levels are associated with RV dys-
function in patients with NETs, including those not ful-
filling the criteria for CHD. Elevated CCN2 levels are also
associated with the presence of at least mild or greater
TR/PR. Our data indicate a role for CCN2 in the develop-
ment and progression of cardiac fibrosis related to NETs,
and suggest that plasma CCN2 may serve as a marker for
the earliest stages of CHD.
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